427 related articles for article (PubMed ID: 22240390)
21. Ascorbyl dipalmitate/PEG-lipid nanoparticles as a novel carrier for hydrophobic drugs.
Moribe K; Maruyama S; Inoue Y; Suzuki T; Fukami T; Tomono K; Higashi K; Tozuka Y; Yamamoto K
Int J Pharm; 2010 Mar; 387(1-2):236-43. PubMed ID: 20005934
[TBL] [Abstract][Full Text] [Related]
22. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
[TBL] [Abstract][Full Text] [Related]
23. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes.
Barauskas J; Cervin C; Jankunec M; Spandyreva M; Ribokaite K; Tiberg F; Johnsson M
Int J Pharm; 2010 May; 391(1-2):284-91. PubMed ID: 20214966
[TBL] [Abstract][Full Text] [Related]
24. Preparation and characterization of paclitaxel delivery system based on semi-solid lipid nanoparticles coated with poly (ethylene glycol).
Wu L; Tang C; Yin C
Pharmazie; 2010 Jul; 65(7):493-9. PubMed ID: 20662317
[TBL] [Abstract][Full Text] [Related]
25. Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Zhang C; Li G; Wang Y; Cui F; Zhang J; Huang Q
Int J Pharm; 2012 Oct; 436(1-2):272-81. PubMed ID: 22721846
[TBL] [Abstract][Full Text] [Related]
26. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats.
Zhao BJ; Ke XY; Huang Y; Chen XM; Zhao X; Zhao BX; Lu WL; Lou JN; Zhang X; Zhang Q
J Drug Target; 2011 Jun; 19(5):382-90. PubMed ID: 20677914
[TBL] [Abstract][Full Text] [Related]
27. PEG conjugated N-octyl-O-sulfate chitosan micelles for delivery of paclitaxel: in vitro characterization and in vivo evaluation.
Qu G; Yao Z; Zhang C; Wu X; Ping Q
Eur J Pharm Sci; 2009 May; 37(2):98-105. PubMed ID: 19429416
[TBL] [Abstract][Full Text] [Related]
28. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
[TBL] [Abstract][Full Text] [Related]
29. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
30. Ascorbyl palmitate/DSPE-PEG nanocarriers for oral iron delivery: preparation, characterisation and in vitro evaluation.
Zariwala MG; Farnaud S; Merchant Z; Somavarapu S; Renshaw D
Colloids Surf B Biointerfaces; 2014 Mar; 115():86-92. PubMed ID: 24333557
[TBL] [Abstract][Full Text] [Related]
31. Design and development of paclitaxel-loaded bovine serum albumin nanoparticles for brain targeting.
Bansal A; Kapoor DN; Kapil R; Chhabra N; Dhawan S
Acta Pharm; 2011 Jun; 61(2):141-56. PubMed ID: 21684843
[TBL] [Abstract][Full Text] [Related]
32. Selective tissue distribution and long circulation endowed by paclitaxel loaded PEGylated poly(ε-caprolactone-co-L-lactide) micelles leading to improved anti-tumor effects and low systematic toxicity.
Wang F; Shen Y; Xu X; Lv L; Li Y; Liu J; Li M; Guo A; Guo S; Jin F
Int J Pharm; 2013 Nov; 456(1):101-12. PubMed ID: 23968782
[TBL] [Abstract][Full Text] [Related]
33. Stealth, biocompatible monoolein-based lyotropic liquid crystalline nanoparticles for enhanced aloe-emodin delivery to breast cancer cells: in vitro and in vivo studies.
Freag MS; Elnaggar YS; Abdelmonsif DA; Abdallah OY
Int J Nanomedicine; 2016; 11():4799-4818. PubMed ID: 27703348
[TBL] [Abstract][Full Text] [Related]
34. Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities.
Wang Z; Ho PC
Small; 2010 Nov; 6(22):2576-83. PubMed ID: 20976704
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and biodistribution of paclitaxel-loaded microspheres.
Yan F; Tang S; Fu Q
Arzneimittelforschung; 2012 Apr; 62(4):176-80. PubMed ID: 22270845
[TBL] [Abstract][Full Text] [Related]
36. Phospholipid-Tween 80 mixed micelles as an intravenous delivery carrier for paclitaxel.
Liang H; Yang Q; Deng L; Lu J; Chen J
Drug Dev Ind Pharm; 2011 May; 37(5):597-605. PubMed ID: 21469948
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers.
Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q
Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003
[TBL] [Abstract][Full Text] [Related]
38. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery.
Wu H; Zhu L; Torchilin VP
Biomaterials; 2013 Jan; 34(4):1213-22. PubMed ID: 23102622
[TBL] [Abstract][Full Text] [Related]
39. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
[TBL] [Abstract][Full Text] [Related]
40. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.
Agüeros M; Zabaleta V; Espuelas S; Campanero MA; Irache JM
J Control Release; 2010 Jul; 145(1):2-8. PubMed ID: 20347897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]